Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories reported approximately $2.0 billion in continuous glucose monitor (CGM) sales, reflecting a year-over-year organic growth rate of 12.2%, alongside a notable expansion in gross margins and EBIT for 2025. The company's Establish Pharmaceuticals & Nutrition segment demonstrated balanced growth, particularly with double-digit increases in markets such as India and parts of Latin America and the Middle East. Furthermore, Abbott's strong performance in the MedTech sector, coupled with disciplined mergers and acquisitions and sustained margin improvements, underpins a positive outlook for future growth, with expectations of mid-single-digit increases in diagnostics, excluding China, for 2026.

Abbott Laboratories is facing a negative outlook primarily due to disappointing performance across nearly all business segments, particularly in the Devices segment, which traditionally offers stronger results. The company's 2026 sales guidance was below consensus expectations, compounded by a significant decline of 7.1% year-over-year in Nutrition sales, which has necessitated a reduction in revenue forecasts for the company overall. After missing Q4 sales estimates, Abbott's stock experienced a decline of approximately 9-10%, highlighting concerns over the ongoing challenges in their Nutrition division and the anticipated weakness in sales during the first half of 2026.